Welcome to our dedicated page for Exact Sciences SEC filings (Ticker: EXAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exact Sciences Corp (NASDAQ: EXAS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Exact Sciences’ cancer screening and diagnostic testing business, financial performance, and significant corporate events.
For EXAS, key filings include current reports on Form 8-K that describe material developments. One Form 8-K reports quarterly financial results, including revenue contributions from the Screening grouping, which encompasses Cologuard tests and PreventionGenetics, and from the Precision Oncology grouping, which includes global Oncotype DX and therapy selection tests. These filings also discuss non‑GAAP metrics such as adjusted EBITDA, adjusted gross margin, and free cash flow, along with reconciliations and management’s rationale for using these measures.
Another important 8-K details the Agreement and Plan of Merger among Exact Sciences, Abbott Laboratories, and a wholly owned Abbott subsidiary. This filing explains the structure of the proposed merger, the per‑share cash consideration to be paid for Exact Sciences common stock, the treatment of equity awards, the conditions to closing, termination rights, and any potential termination fee. It also notes that Exact Sciences’ board of directors unanimously approved the merger agreement and recommends that stockholders adopt it, subject to customary conditions.
Additional 8-K filings describe a collaboration and license agreement with Freenome Holdings, Inc. for blood‑based colorectal cancer screening tests, as well as other corporate announcements furnished as exhibits, such as earnings press releases and investor communications. These documents provide context on how Exact Sciences is expanding its portfolio in blood‑based screening and multi‑cancer early detection.
On Stock Titan, investors can review these SEC filings as they are made available through EDGAR. AI‑powered tools can help summarize lengthy disclosures, highlight key terms of material agreements, and surface notable changes in guidance, capital structure, or strategic direction, enabling users to quickly understand the implications of new EXAS filings.
Exact Sciences Corp — Schedule 13G/A (Amendment No. 12)
The Vanguard Group reports 0 shares beneficially owned of Exact Sciences common stock, representing 0% of the class. The filing states Vanguard completed an internal realignment on January 12, 2026, after which certain subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
Exact Sciences EVP Brian Baranick reported changes in his equity as the Abbott acquisition closed. On March 23, 2026, Exact Sciences merged into a wholly owned Abbott subsidiary, with each share of Exact common stock converted into the right to receive $105.00 in cash.
At the merger’s effective time, his performance-based restricted stock units became fully vested based on actual performance levels and were cancelled for cash at $105.00 per underlying share. His outstanding restricted stock units were disposed of or converted, and his Exact common stock holdings, including shares in a 401(k) plan, were surrendered to the issuer, leaving no remaining Exact holdings reported after these transactions.
Certain restricted stock units granted on or after November 19, 2025 were assumed by Abbott as replacement restricted stock units on substantially the same terms, with the new awards vesting in four equal annual installments beginning on February 25, 2027.
Exact Sciences Corporation senior vice president and general counsel James Herriott reported the final treatment of his equity as the company was acquired by Abbott Laboratories. On the March 23, 2026 merger closing, each Exact Sciences common share was converted into the right to receive $105.00 in cash, without interest.
Herriott’s outstanding stock options were cancelled and, where the exercise price was below $105.00 per share, converted into a cash right equal to the spread over the merger price, less taxes. His Exact Sciences restricted stock units were similarly terminated as issuer awards, with RSUs granted on or after November 19, 2025 assumed by Abbott as new parent RSUs on substantially the same terms.
This Form 4 records a series of dispositions to the issuer, not open‑market trades, and reflects that Herriott no longer holds Exact Sciences equity following the merger, with his continuing equity exposure now in Abbott equity-based awards.
EXACT SCIENCES CORP EVP and Chief Financial Officer Aaron Bloomer reported a series of equity changes tied to the company’s merger with Abbott Laboratories. At the merger’s effective time, each share of Exact common stock and each vested equity unit was converted into the right to receive $105.00 in cash per share, less applicable taxes.
The filing shows performance-based and time-based restricted stock units being fully vested, cancelled, and exchanged for this cash consideration, while certain newer RSUs were assumed as Abbott restricted stock units on substantially the same terms. Following these transactions, the Form 4 indicates no remaining Exact Sciences common stock or RSU holdings for Bloomer.
Exact Sciences EVP of Human Resources Sarah Condella reported a series of equity adjustments tied to the completion of the company’s merger with Abbott Laboratories. On March 23, 2026, Badger Merger Sub I merged into Exact Sciences, making Exact a wholly owned subsidiary of Abbott.
At the effective time of the merger, each share of Exact common stock outstanding was converted into the right to receive $105.00 in cash per share. Performance-based restricted stock units became fully vested based on achievement levels as of November 19, 2025 and were cancelled for the same $105.00 per-share cash consideration, less applicable tax withholding.
Stock options with exercise prices below $105.00 were cancelled and converted into cash equal to the spread between $105.00 and the option exercise price, multiplied by the number of underlying shares. Restricted stock units granted on or after November 19, 2025 were assumed by Abbott as Abbott restricted stock units on substantially the same terms.
Exact Sciences Corporation completed its merger with a subsidiary of Abbott Laboratories on March 23, 2026, with Exact Sciences becoming a wholly owned Abbott subsidiary. At the merger’s effective time, each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash per share, subject to tax withholding.
For President and CEO Kevin T. Conroy, all reported stock options and restricted stock units were cancelled and treated in cash or converted into Abbott equity under the merger agreement. In-the-money options were cancelled for a cash payment based on the $105.00 merger consideration minus the option exercise price, while performance-based and time-based RSUs were either fully vested and paid in cash or assumed as Abbott restricted stock units. Following these transactions, the filing shows no remaining Exact Sciences common stock or derivatives reported for Conroy.
EXACT SCIENCES CORP EVP and GM of Screening Jacob A. Orville reported merger-related equity changes tied to the company’s acquisition by Abbott Laboratories. In the merger, each share of common stock was converted into the right to receive $105.00 in cash.
On March 23, 2026, the executive disposed of stock options, restricted stock units, and common shares (including 401(k) holdings) back to the issuer as part of the transaction and received a grant of 53,323 shares of common stock as a compensation award. The new award vests in four equal annual installments beginning on February 25, 2027.
Exact Sciences Corporation director D. Scott Coward reported the cancellation and disposition of his equity in connection with the company’s merger with Abbott Laboratories. At the merger’s effective time, each Exact Sciences common share was converted into the right to receive $105.00 in cash, without interest. Coward’s restricted and other common shares, including shares held in a 401(k) plan, were deemed fully vested, cancelled, and converted into the cash merger consideration, subject to tax withholding. His outstanding stock options with exercise prices below $105.00 were cancelled and converted into cash equal to the spread between $105.00 and the option exercise price, multiplied by the underlying shares. Following these issuer dispositions, the Form 4 shows he no longer holds Exact Sciences common stock or related stock options.
Exact Sciences director Shacey Petrovic reported disposing of all common stock holdings in connection with the closing of Exact Sciences’ merger with Abbott Laboratories. The Form 4 shows issuer dispositions of 16,406 and 5,398 directly held shares, plus 7,095 shares held indirectly in a grantor retained annuity trust.
According to the merger terms, at the effective time each share of Exact Sciences common stock was converted into the right to receive $105.00 in cash, without interest. All restricted shares outstanding immediately before the merger became fully vested, were cancelled, and likewise converted into the cash merger consideration (less any applicable tax withholding).